logo
Figma's $21 Billion Drop Returns Stock to Earth After IPO Frenzy

Figma's $21 Billion Drop Returns Stock to Earth After IPO Frenzy

Bloomberg3 days ago
Figma Inc. has taken investors who pounced on the year's hottest initial public offering for a wild ride, shedding $21 billion from a peak in the days following its record-breaking IPO.
The San Francisco-based company's shares have been trading on-and-off all week below the $85 level, where they opened on July 31, their first day in the market. Despite modest rebounds, the design software firm's stock has given back much of the increase that briefly mesmerized Wall Street.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ford's Secret Weapon to Beat Tesla Is a $30,000 EV Truck
Ford's Secret Weapon to Beat Tesla Is a $30,000 EV Truck

Gizmodo

timea minute ago

  • Gizmodo

Ford's Secret Weapon to Beat Tesla Is a $30,000 EV Truck

Just as the American EV market braces for a potential collapse, Ford is making a shocking pivot. With federal tax credits set to disappear on September 30 and demand expected to plummet, the automaker is doubling down with an additional $2 billion investment in battery-electric vehicles (BEVs). But it's doing so with a new strategy borrowed not from its American rivals, but directly from China. The centerpiece of this bet is a new midsize electric pickup with a targeted base price of just $30,000. CEO Jim Farley announced, on Monday, the unnamed vehicle at an event in Louisville, Kentucky, where it will be assembled, with a planned market arrival in 2027. 'This new truck, based on this universal platform, is going to be more spacious inside than the RAV4, the best-selling car in the United States,' Farley declared, directly targeting the king of the gasoline SUV market. 'But it will have a frunk and it will have a whole pickup truck bed behind it. No one has seen this kind of flexibility.' Recent reports suggest the new EV pickup could be a revival of the Ranchero. According to the site Ford Authority, the company has filed a new trademark for the name, specifically for use on electric pickup trucks. The Ranchero, a car-truck hybrid not seen on U.S. roads since 1979, was a cult classic that offered the comfort of a sedan with the utility of a pickup bed. This move marks a radical departure for Ford. It's a break from its American competitors, notably Tesla, which has focused on premium vehicles like the commercially struggling Cybertruck. It's also a break from Ford's own profitable strategy of selling large, expensive pickups and SUVs like the F-150 and Expedition. Instead, Ford is adopting a strategy that looks much more like that of Chinese automaker BYD, which has become the world's largest EV seller by specializing in affordable electric cars. The cheapest BYD EV, the Seagull, starts at the equivalent of just $9,700 in China. This focus on affordability has allowed BYD to steal massive market share from Tesla in both China and Europe. After the Mustang, Ford Is Teasing the Return of Another Beloved Car As an EV Farley acknowledged that many current EVs don't address what buyers actually want. 'A computer can have much lower costs—that's why we redid this platform… to bring the costs down,' he told CNBC. So how does Ford plan to build a low-cost, high-performance pickup that no other American automaker has managed? By completely reinventing its design and manufacturing process. A secret 'skunkworks' team created, the carmaker said, the new 'Ford Universal EV Platform,' a simplified architecture using 20% fewer parts and 25% fewer fasteners. The wiring harness alone is 4,000 feet shorter. The battery is another key. Ford is manufacturing its own cobalt-free LFP prismatic batteries in Michigan. This chemistry is, Ford claimed, significantly cheaper, and its design allows it to serve as a structural part of the truck's floor, saving space and cost. Finally, Ford has reinvented the factory itself. Instead of the traditional moving assembly line, the new truck will be built using an 'assembly tree.' The vehicle is built in three main sub-assemblies—the front, the rear, and the structural battery floor with the interior already attached—which are then joined at the end. Ford claims this revolutionary process is 15% faster and considerably simpler. 'Our idea is that the people working here in Louisville will be able to buy this car and spend money on other things they love, like vacations, their home, and their children's education,' Farley said. This new truck is a direct challenge to the entire auto industry. But it comes as Ford's own EV division is struggling. In the second quarter of 2025, the unit recorded an operating loss of $1.3 billion. The company is betting that this radical new approach, borrowed from China and powered by American innovation, is the only way to finally make EVs profitable for the company and affordable for everyone else.

8 Out of Top 10 Countries for U.S. Tourism Showed Declines in July
8 Out of Top 10 Countries for U.S. Tourism Showed Declines in July

Skift

timea minute ago

  • Skift

8 Out of Top 10 Countries for U.S. Tourism Showed Declines in July

Tourism to the U.S. from overseas has declined for 5 of the past 6 months. Higher visa fees and other restrictions could make it worse. Overseas visits to the U.S. dropped 3.1% in July, extending a slide that began earlier this year, according to preliminary government data released Monday. The National Travel and Tourism Office reported that arrivals from Western Europe fell 4% year-over-year, driven by a steep 14.7% drop from Germany. Other major declines came from China (down 13.8%), Switzerland (down 12.7%), the Netherlands (down 7.2%), and India (down 5.5%). Visits have fallen in five of the past six months, with April the one exception, when there was a 1% gain. The data excludes arrivals from Canada and Mexico, the two largest inbound markets for the U.S. In June, air travel by Canadians to the U.S. dropped 22% and car crossings dropped 33%, the sixth straight month of declines, according to Statistics Canada. Overall, eight of the top 10 overseas markets for U.S. tourism saw year-over-year declines in July. The only gains came from Japan and Italy. UK: – 0.4% India: -5.5% France: -0.2% Japan: + 9.1% Germany: – 14.7% Brazil: -1.7% South Korea: – 0.8% China: – 13.8% Italy: + 6.3% Colombia: – 0.3% The declines have coincided with increased global tensions related to rhetoric from the Trump administration and tough negotiations over tariffs. In addition, there were several isolated but highly publicized reports of tourists being detained at U.S. checkpoints and the U.S. has resurrected travel bans and other travel restrictions. The recently passed tax and spending law – 'One Big Beautiful Bill Act' – includes an 80% reduction in federal funding for Brand USA, which markets the U.S. abroad as a tourist destination.

FDA Okays Ketamine-Based Med for Post-Surgical Pain
FDA Okays Ketamine-Based Med for Post-Surgical Pain

Medscape

timea minute ago

  • Medscape

FDA Okays Ketamine-Based Med for Post-Surgical Pain

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical pain. 'This historic FDA approval…is a testament to years of dedicated development,' Fabio Chianelli, chairman and CEO of PharmaTher, said in a release. 'We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders,' he added. The company noted that it hopes to expand ketamine development into conditions such as Parkinson's disease, amyotrophic lateral sclerosis, depression, and complex regional pain syndrome. Its product has already received an orphan drug designation for the treatment of Rett syndrome. It added that, among psychedelic and 'psychedelic-adjacent' drugs, ketamine is the only one to be included on a list of Essential Medicines by the World Health Organization. The company initially announced that the FDA had set an approval goal date of April 2024 for KETARx. However, after 'minor deficiencies identified by Quality' were identified, the FDA assigned a new target date of October 2024. As reported by Medscape Medical News at the time, the FDA issued a complete response letter requesting additional information on the application. The final date of August 2025 was set after the company submitted the requested additional information.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store